Immunotherapeutic Approaches Have the Potential to Brighten the Future Not ... Cancer Network As critically discussed by the authors, a multitude of previous trials and currently available treatment regimens, including rituximab-based chemo-immunotherapy, have largely failed to show satisfactory efficacy in patients with del(17p13.1), both in ... |
